Trade Stoke Therapeutics, Inc. - STOK CFD

Trading Conditions

• Spread: 0.06
• Long position overnight feeLong position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position-0.026179 %(-$1.05)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position0.003957 %($0.16)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-$1.05)

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  ($0.16)

Key Stats

• Prev. Close: 11
• Open: 11.32
• 1-Year Change: 27.91%
• Day's Range: 11.15 - 11.43

Stoke Therapeutics, Inc. Company profile

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc. is a biotechnology company. It focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. It is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. It focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. It utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Stoke Therapeutics Inc revenues was not reported. Net loss increased 64% to $85.8M. Higher net loss reflects Research and development - Balancing val increase of 58% to $48M (expense), Stock-based Compensation in SGA increase from $3.9M to $10.2M (expense), General and administrative - Balancing increase of 28% to $21.7M (expense).